| Q43543016 | 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT(1B/1D) receptor agonist activity? |
| Q43621340 | 4991W93, a potent blocker of neurogenic plasma protein extravasation, inhibits trigeminal neurons at 5-hydroxytryptamine (5-HT1B/1D) agonist doses |
| Q32041979 | A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation |
| Q48228390 | Autoradiographic studies of 5-HT1A-receptor-stimulated [35S]GTPgammaS-binding responses in the human and monkey brain |
| Q77164374 | BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential |
| Q37785745 | CGRP and its receptors provide new insights into migraine pathophysiology |
| Q40875330 | Characterization of ligand binding properties of the 5-HT1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors |
| Q35569299 | Contemporary concepts of migraine pathogenesis |
| Q41371780 | Current concepts of the pathophysiology of migraine |
| Q51544635 | Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. |
| Q24672188 | Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands) |
| Q42709798 | Effect of a 5‐HT1 receptor agonist, CP‐122,288, on oedema formation induced by stimulation of the rat saphenous nerve |
| Q73098697 | Effects of alniditan on neurogenic oedema in the rat dura mater and on contraction of rat basilar artery |
| Q41460269 | How do the currently used prophylactic agents work in migraine? |
| Q46396557 | Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation |
| Q48249368 | Magnitude of 5-HT1B and 5-HT1A receptor activation in guinea-pig and rat brain: evidence from sumatriptan dimer-mediated [35S]GTPgammaS binding responses |
| Q41671906 | Migraine to the Year 2000 |
| Q36871287 | Molecular cloning and pharmacological characterization of guinea pig 5-HT1B and 5-HT1D receptors |
| Q28291139 | Neurogenic Model of Migraine |
| Q34218309 | Neurogenic inflammation in the context of migraine |
| Q81351572 | Neuroprotective effect of sumatriptan, a 5-HT(1D) receptor agonist, in focal cerebral ischemia of rat brain |
| Q47676203 | Perivascular neurotransmitters: Regulation of cerebral blood flow and role in primary headaches. |
| Q47965497 | Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor: a central action in migraine? |
| Q34793190 | Suppression by the sumatriptan analogue, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin |
| Q46838016 | The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater |
| Q34373285 | The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP-122,288, a selective inhibitor of neurogenic inflammation |
| Q34558808 | The medical benefit of 5-HT research |
| Q34663175 | The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs |
| Q33952000 | The pharmacology of headache |
| Q34299099 | The pre- and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan |
| Q48559123 | The selectivity of MDL 74,721 in models of neurogenic versus vascular components of migraine |
| Q42116885 | Trigeminal nerve ganglion stimulation-induced neurovascular reflexes in the anaesthetized cat: role of endothelin(B) receptors in carotid vasodilatation |
| Q34373438 | [3H]sumatriptan labels both 5-HT1D and 5-HT1F receptor binding sites in the guinea pig brain: an autoradiographic study |